In–vitro Bioequivalence Study Between four Different Marketed Formulations of Gliclazide with Sustained Release Metformin Hydrochloride Tablet as an Anti-Diabetic Drug
Abstract
As per the granted biowaiver by the United States Food and Drug Administration, the in-vitro method is an alternative to find out bioequivalence. In the performed study, a finished product test was performed between the brand drug and the generic drugs to find out the consistency of generic drugs. In the recent era, generic medicine is encircled all over the market to reduce the cost of medicine so that the drug to be available to all the individual in minimum prices for that In-Vitro Bioequivalence is conducted for a different formulation of drugs for the assessment of different formulation of same drugs or alike active pharmaceutical ingredients. The main objective of this study is to find out the in-vitro bioequivalence, evaluate the parameters which impact on dissolution profile, and assemble the research work.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.